Merck KGaA is open to more acquisitions, but not for its CDMO unitnews2025-10-16T15:18:38+00:00October 16th, 2025|Endpoints News|
Novo Nordisk buys kidney, blood disorder drug from Omerosnews2025-10-15T14:02:15+00:00October 15th, 2025|Endpoints News|
Post-Hoc Live: Are the good times in biotech … back?news2025-10-15T11:33:01+00:00October 15th, 2025|Endpoints News|
Which big pharma had the busiest M&A team? Q3 biopharma deal analysisnews2025-10-15T11:00:20+00:00October 15th, 2025|Endpoints News|
J&J CEO downplays any need for ‘large’ acquisition as it gears up for new launchesnews2025-10-14T17:41:05+00:00October 14th, 2025|Endpoints News|
BioCryst to acquire Astria for $700M, adding a second HAE drugnews2025-10-14T15:13:14+00:00October 14th, 2025|Endpoints News|
Johnson & Johnson to spin out orthopedics businessnews2025-10-14T11:01:12+00:00October 14th, 2025|Endpoints News|
Bristol Myers, insitro extend ALS drug research dealnews2025-10-14T11:00:40+00:00October 14th, 2025|Endpoints News|
Takeda, Nabla Bio sign second research deal for AI-made proteinsnews2025-10-14T09:00:52+00:00October 14th, 2025|Endpoints News|
Biopharma dealmaking trends: Q3 shows an upticknews2025-10-13T11:00:59+00:00October 13th, 2025|Endpoints News|
